Michael Murray, ND

Dr. Michael Murray joins Enzymedica

Takes on the role of chief science officer at the digestive enzyme supplement company, after leaving his post at Natural Factors last year.

Enzymedica Inc. is excited to announce that Dr. Michael Murray, author of more than 30 books, including The Encyclopedia of Natural Medicine, and an individual who has been recently named "The Voice of Natural Medicine" by Nutrition Business Journal, has joined the company as chief science officer.

According to Scott Sensenbrenner, CEO, "Dr. Murray is a true icon in the natural health movement and brings tremendous credibility, experience and passion to our company."

Dr. Murray will be critical to driving new innovations in product development for Enzymedica, as well as leading research efforts to create next-generation formulas that will be groundbreaking for the industry.  

In addition to his role with Enzymedica, Dr. Murray will be working closely with the Roskamp Institute in Sarasota, Florida. This nonprofit organization is performing cutting-edge research for organizations like the National Institutes of Health, Department of Defense and the European Union. Roskamp is renowned for its team's research on Alzheimer's disease, Gulf War Illness and other complex diseases. Dr. Murray and the institute will be developing better answers for improving brain health, the human microbiome and digestion.

Enzymedica's strategic relationship with the Roskamp Institute gives it the resources and expertise critical for providing innovative, science-based natural products, furthering its contribution to digestive health. This close partnership is further demonstrated by Sensenbrenner, who serves on the board of directors of the Roskamp Institute.

Dr. Murray says, "I am thrilled to be part of the team at both Enzymedica and the Rosskamp Institute. It is a dream come true."

Sensenbrenner and Dr. Murray previously worked together in the 1990s at Enzymatic Therapy, which was later acquired by the German company Dr. Wilmarr Schwabe Pharmaceuticals.

Source: Enzymedica press release

 

TAGS: General
Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish